Document

______________________________________________________________________________
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________
FORM 8-K
____________________________________________
CURRENT REPORT
Pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 12, 2020
_____________________________________________
BioDelivery Sciences International, Inc.
(Exact name of registrant as specified in its charter)
_______________________________________________
Delaware001-3136135-2089858
(State or other jurisdiction(Commission(IRS Employer
of incorporation)File Number)Identification No.)
4131 ParkLake Ave., Suite #225
Raleigh, NC27612
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: 919-582-9050
Not Applicable
(Former name or former address, if changed since last report)
________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
ACTIVE/103405904.1




Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.001BDSIThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

______________________________________________________________________________________________________
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
Retirement of Director

On May 12, 2020, Frank E. O'Donnell Jr, MD notified BioDelivery Sciences International, Inc. (the “Company”) that he has decided to resign, effective as of May 12, 2020 (the “Retirement Date”), as a member of the Company’s Board of Directors. There are no disagreements between Dr. O'Donnell and the Company on any matter relating to the Company’s operations, policies or practices.
______________________________________________________________________________________
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
May 12, 2020  BIODELIVERY SCIENCES INTERNATIONAL, INC.
  By: /s/ Mary Theresa Coelho
  Name: Mary Theresa Coelho
  Title: Chief Financial Officer and Treasurer
 
 
ACTIVE/103405904.1